The safety and efficacy of apixaban: Where do we stand in 2013?

Expert Opinion on Drug Safety

Volumn 12, Issue 4, 2013, Pages 559-567

  De Souza Brito, Flavio ^a   Lopes, Renato D ^a   Alexander, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Apixaban; Atrial fibrillation; Oral direct selective factor Xa inhibitor; Orthopedic surgery; Stroke; Venous thromboembolic event

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BMS 532247; DABIGATRAN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRT 4445; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; ORTHOPEDIC SURGERY; PHARMACODYNAMICS; REVIEW; SECONDARY PREVENTION; SINGLE DRUG DOSE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FACTOR XA; HUMANS; PYRAZOLES; PYRIDONES;

EID: 84879391775     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.799663     Document Type: Review

References (28)

1. Roger VL, Go AS, Lloyd-Jones DM, Heart disease and stroke statistics 2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209
2. Roser-Jones C, Becker RC. Apixaban: an emerging oral factor Xa inhibitor. J Thromb Thrombolysis 2010;29:141-6
3. Nutescu E, Rhoades R, Bailey C, Apixaban: a novel oral inhibitor of factor Xa. Am J Health Syst Pharm 2012;69:1113-26
4. Pinto DJ, Orwat MJ, Koch S, Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4- (2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-56 (Pubitemid 350057846)
5. Wang L, Raghavan N, He K, Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos 2009;37:802-8
6. Yamahira N, Imail Y, Yu Z, A placebo-controlled, ascending multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of apixaban in Japanese healthy adult male subjects [abstract]. Can J Clin Pharmacol 2008;15:e719
7. Zhang D, He K, Raghavan N, Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. J Thromb Thrombolysis 2010;29:70-80
8. Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011;31:478-92
9. Zhang D, He K, Raghavan N, Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 2009;37:1738-48
10. Raghavan N, Frost CE, Yu Z, Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81
11. Connolly SJ, Eikelboom J, Joyner C, Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17
12. Granger CB, Alexander JH, McMurray JJ, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
13. Raskob GE, Gallus AS, Pineo GF, Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012;94:257-64
14. Imberti D, Gallerani M, Manfredini R. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J Thromb Thrombolysis 2012;34:208-13
15. Lassen MR, Raskob GE, Gallus A, Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
16. Lassen MR, Raskob GE, Gallus A, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15
17. Lassen MR, Gallus A, Raskob GE, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98
18. Levine MN, Gu C, Liebman HA, A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012;10:807-14
19. Goldhaber SZ, Leizorovicz A, Kakkar AK, Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365:2167-77
20. Agnelli G, Buller HR, Cohen A, Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368(8):699-708
21. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. ClinicalTrials.gov: NCT00633893. Available from: www. clinicaltrials.gov/ct2/show/NCT00633893 [Last accessed 15 April 2013]
22. Alexander JH, Becker RC, Bhatt DL, Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-85
23. Alexander JH, Lopes RD, James S, Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708
24. Lu G, DeGuzman FR, Lakhotia S, Recombinant antidote for reversal of anticoagulation by Factor Xa inhibitors. Blood 2008;112:362
25. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9
26. Hohnloser SH, Hijazi Z, Thomas L, Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-30
27. Lopes RD, Al-Khatib SM, Wallentin L, Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012;380:1749-58
28. Oldgren J, Alings M, Darius H, Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011;155:660-7